Plain-English translation of NCT07209189 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
The NeoScorch HN trial is testing a new approach for treating advanced head and neck cancer. Patients receive a combination of chemotherapy and an immune-boosting medication called before surgery, followed by radiation and/or additional chemotherapy after surgery. The goal is to shrink tumors enough that patients may need less extensive surgery, which could help preserve their ability to swallow, speak, and see.
Standard treatment for advanced head and neck cancer often requires aggressive surgery that can cause serious side effects like difficulty swallowing and speaking. Researchers believe that giving the medication before surgery might shrink tumors enough to allow for less invasive surgical approaches while maintaining the same cancer-fighting effectiveness.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy combined with (the immune-boosting medication) for several cycles before undergoing surgery. After surgery heals, you would receive radiation therapy and/or additional chemotherapy, followed by more doses of . Throughout the trial, you'll have regular blood tests, imaging scans, and clinic visits to monitor how well the treatment is working and to check for side effects. The entire process typically takes several months.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States